Trial | NCT00542295  Report issue

Title

Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome
Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    400
To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design
Study Started
Jul 31
2007
Primary Completion
Jul 31
2008
Study Completion
Sep 30
2008
Last Update
Oct 01
2008
Estimate

Drug alverine citrate and simeticone

  • Other names: Meteospasmyl®

Drug placebo

A Experimental

B Placebo Comparator

Criteria 

Inclusion Criteria:

male or female ambulatory patients, aged 18-75 years
with IBS as defined by Rome III criteria

Exclusion Criteria:

Functional bowel disorder other than IBS,
Underlying cause for symptomatology, which excludes IBS diagnosis,
Gastro-intestinal cancer or significant gastro-intestinal surgical background,
Any acute/uncontrolled systemic pathology
No Results Posted